VistaGen's AV-101 Featured in Peer-Reviewed Publication

VistaGen Therapeutics (NASDAQ:VTGN) announced the publication of a nonclinical study on the effects of AV-101, the company’s central nervous system disorder drug.
As quoted in the press release:

The publication, titled: “Characterization of the effects of L-4-chlorokynurenine on nociception in rodents,” by lead author, Tony L. Yaksh, Ph.D., and co-authors, Robert Schwarcz, Ph.D. and H. Ralph Snodgrass, Ph.D., was recently published in The Journal of Pain (DOI: 10.1016/j.jpain.2017.03.014) and is available online at https://www.jpain.org/article/S1526-5900(17)30552-7/abstract.
“In these studies, AV-101 was found to have robust anti-nociceptive effects, similar to gabapentin, but with a better side effect profile in several pre-clinical models of hyperalgesia and allodynia, results suggest AV-101’s potential for treating multiple hyperpathic pain states,” reported Tony L. Yaksh, Ph.D., Professor in Anesthesiology at the University of California, San Diego (UCSD).

Click here to read the full press release.

Source: www.marketwired.com